

Filed On Behalf Of:

Alkermes Pharma Ireland Limited and
Alkermes Controlled Therapeutics, Inc.

By:

Scott K. Reed
sreed@fchs.com
212-218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

**LUYE PHARMA GROUP LTD., LUYE PHARMA(USA) LTD.,
SHANDONG LUYE PHARMACEUTICAL CO., LTD., and NANJING
LUYE PHARMACEUTICAL CO., LTD.,**

Petitioners,

v.

**ALKERMES PHARMA IRELAND LTD and ALKERMES CONTROLLED
THERAPEUTICS, INC.,
Patent Owners.**

Case IPR2016-01096
U.S. Patent No. 6,667,061

PATENT OWNERS' EXHIBIT LIST 4

EXHIBIT LIST 4

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner Alkermes Pharma Ireland

Limited (“Alkermes”) respectfully submits the following current exhibit list.

Alkermes Exhibit No.	Description
2001	Patrick P. DeLuca & James C. Boylan, <i>Chapter 5: Formulation of Small Volume Parenterals</i> , in PHARMACEUTICAL DOSAGE FORMS: PARENTERAL MEDICATIONS 173-248 (Kenneth E. Avis et al. eds., 2 nd ed. 1992).
2002	U.S. PHARMACOPEIA xxii-xxx (1995 ed.).
2003	EUROPEAN PHARMACOPEIA iii-vi, 1-10 (3rd ed. 1997).
2004	Intentionally Left Blank
2005	Intentionally Left Blank
2006	Intentionally Left Blank
2007	Intentionally Left Blank
2008	S.L. Phillips et al., <i>Viscosity of NaCl and other solutions up to 350°C and 50 MPa pressures</i> , U.S. DEPT. ENERGY (1980).
2009	J. R. Nixon & B. P. S. Chawla, <i>Viscosity and stability relations of the system ascorbic acid: water: polysorbate 20</i> , 17 J. PHARMACY & PHARMACOLOGY 558-65 (1965).
2010	February 2, 2017 Declaration in Support of Patent Owners’ Motion for Pro Hac Vice Admission of Ha Kung Wong
2011	February 2, 2017 Declaration in Support of Patent Owners’ Motion for Pro Hac Vice Admission of Christina Schwarz
2012	February 2, 2017 Declaration in Support of Patent Owners’ Motion for Pro Hac Vice Admission of Melinda R. Roberts
2013	February 2, 2017 Declaration in Support of Patent Owners’ Motion for Pro Hac Vice Admission of Una Fan

Alkermes Exhibit No.	Description
2014	March 8, 2017 Declaration of Dr. Cory Berkland.
2015	Curriculum Vitae of Dr. Cory Berkland.
2016	February 22, 2017 Deposition Testimony of Dr. Patrick DeLuca.
2017	K.E. Avis, <i>Chapter 21: Particle Phenomena and Coarse Dispersions</i> , in REMINGTON'S PHARM. SCI. 301-329 (A.R. Gennaro et al. eds., 17 th ed. 1985).
2018	K.E. Avis, <i>Chapter 68: Particle Phenomena and Coarse Dispersions</i> , in REMINGTON'S PHARM. SCI. 1306 (A.R. Gennaro et al. eds., 17 th ed. 1985).
2019	U.S. FOOD AND DRUG ADMIN., Medical Review, Risperdal [®] Consta [®] Long-Acting Injection NDA No. 21-346, approved Oct. 29, 2003.
2020	S. D'Souza, J.A. Faraj, S. Giovagnoli, & P.P. DeLuca, <i>Dev. of Risperidone PLGA Microspheres</i> , 2014 J. DRUG DELIVERY Art. ID 420624 (2014).
2021	Y. Capan, G. Jiang, S. Giovagnoli, K.H. Na, & P.P. DeLuca, <i>Preparation and Characterization of Poly(D,L-lactide-co-glycolide) Microspheres for Controlled Release of Human Growth Hormone</i> , 4(2) AAPS PHARMSciTECH Art. 28 (2003).
2022	K.W. Burton, M. Shameem, B.C. Thanoo, & P.P. DeLuca, <i>Extended release peptide delivery systems through the use of PLGA microsphere combinations</i> , 11(7) J. BIOMATERIALS SCI. POLYMER ED. 715-29 (2000).
2023	H.B. Ravivarapu, H. Lee, & P.P. DeLuca, <i>Enhancing Initial Release of Peptide from Poly(d,l-lactide-co-glycolide) (PLGA) Microspheres by Addition of a Porosigen and Increasing Drug Load</i> , 5(2) PHARM. DEV. & TECH. 287-96 (2000).
2024	H.B. Ravivarapu, K. Burton, & P.P. DeLuca, <i>Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres</i> , 50 EUR. J. PHARM. & BIOPHARM. 263-70 (2000).
2025	J.W. Kostanski, B.A. Dani, G.A. Reynolds, C.Y. Bowers, & P.P. DeLuca, <i>Evaluation of Orntide Microspheres in a Rat Animal Model and Correlation to In Vitro Release Profiles</i> , 1(4) AAPS PHARMSciTECH Art. 27 (2000).

Alkermes Exhibit No.	Description
2026	B.H. Woo, J.W. Kostanski, S. Gebrekidan, B.A. Dani, B.C. Thanoo, & P.P. DeLuca, <i>Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres</i> , 75 J. CONTROLLED RELEASE 307-15 (2001).
2027	B.A. Dani & P.P. DeLuca, <i>Preparation, Characterization, and In Vivo Evaluation of Salmon Calcitonin Microspheres</i> , 2(4) AAPS PHARMSciTECH Art. 22 (2001).
2028	B.H. Woo, K.H. Na, B.A. Dani, G. Jiang, B.C. Thanoo, & P.P. DeLuca, <i>In Vitro Characterization and in Vivo Testosterone Suppression of 6-Month Release Poly(D,L-Lactide) Leuprolide Microspheres</i> , 19(4) PHARM. RES. 546-50 (2002).
2029	G. Jiang, W. Qiu, & P.P. DeLuca, <i>Preparation and in Vitro/in Vivo Evaluation of Insulin-Loaded Poly(Acryloyl-Hydroxyethyl Starch)-PLGA Composite Microspheres</i> , 20(3) PHARM. RES. 452-59 (2003).
2030	P.P. DeLuca et al., Patent App. Pub. No. US 2007/0122487.
2031	S. Duggirala & P.P. DeLuca, <i>Rheological Characterization of Cellulosic and Alginate Polymers</i> , PDA J. PHARM. SCI. & TECH. 50(5): 290-96 (1996).
2032	A.R. Hurwitz, P.P. DeLuca, & H.B. Kostenbauder, <i>Binding of Organic Electrolytes by a Nonionic Surface-Active Agent</i> , J. PHARM. SCI. 52(9): 893-97 (1963).
2033	P.P. DeLuca, <i>Chapter 32: Parenteral Products: Design and Optimization, Including Freeze Drying</i> , in TOPICS IN PHARM. SCI. 471-91 (D.J.A. Crommelin et al. eds., 1994).
2034	<i>Aqualon Sodium Carboxymethylcellulose: Physical and Chemical Properties</i> , AQUALON (1999).
2035	X.H. Yang & W.L. Zhu, <i>Viscosity properties of sodium carboxymethylcellulose solutions</i> , CELLULOSE 14(5):409-17 (2007).
2036	<i>Carboxymethylcellulose</i> , DOW CHEMICAL, available at http://www.dow.com/dowwolff/en/industrial_solutions/polymers/carboxymethylcellulose/ (last visited March 1, 2017).
2037	U. Florjancic et al., <i>Rheological Characterization of Aqueous Polysaccharide Mixtures Undergoing Shear</i> , CHEM. BIOCHEM. ENG. Q. 16(3): 105-18 (2002).

Alkermes Exhibit No.	Description
2038	<i>Performance Specialties Reference Guide</i> , ASHLAND, available at http://www.brenntag.com/media/documents/bsi/product_data_sheets/material_science/ashland_polymers/performance_specialties_reference_guide.pdf (last visited Mar. 1, 2017).
2039	Specification Sheet-Sodium carboxymethyl cellulose-ultra low viscosity, SIGMA-ALDRICH, available at http://www.sigmaaldrich.com/catalog/DataSheetPage.do?brandKey=ALDRICH&symbol=360384 (last visited March 1, 2017).
2040	Specification Sheet-Carboxymethylcellulose sodium-low viscosity, SPECTRUM CHEMICAL, available at https://www.spectrumchemical.com/MSDS/CA193-AGHS.pdf (last visited March 1, 2017).
2041	U.S. FOOD AND DRUG ADMIN., Clinical Pharm. and Biopharm. Review, Risperdal [®] Consta [®] Long-Acting Injection NDA No. 21-346, approved Oct. 29, 2003.
2042	A. Benchabane & K. Bekkour, <i>Rheological properties of carboxymethyl cellulose (CMC) solutions</i> , 286 COLLOID POLYMER SCI. 1173-80 (2008).
2043	J.H. Guo et al., <i>Pharmaceutical applications of naturally occurring water-soluble polymers</i> , PHARM. SCI. & TECH. TODAY 1(6): 254-61 (1998).
2044	S.I. Conceicao et al., <i>Influence of deagglomeration and carboxymethyl cellulose binders on rheological behaviour of kaolin suspensions</i> , APPLIED CLAY SCI. 23: 257-64 (2003).
2045	M. Bonferoni et al., <i>Influence of medium on dissolution-erosion behavior of Na carboxymethylcellulose and on viscoelastic properties of gels</i> , INT'L J. PHARM. 117: 41-48 (1995).
2046	P. Sebert et al., <i>Gamma irradiation of carboxymethylcellulose: technological and pharmaceutical aspects</i> , INT'L J. PHARM. 106: 103-08 (1994).
2047	J. Wang & P. Somasundaran, <i>Adsorption and conformation of carboxymethylcellulose at solid-liquid interfaces using spectroscopic, AFM and allied techniques</i> , J. COLLOID & INTERFACE SCI. 291: 75-83 (2005).
2048	Y.C.J. Wang, <i>Chapter 7: Parenteral Products of Peptides and Proteins</i> , in 1 PHARM. DOSAGE FORMS: PARENTERAL MEDICATIONS

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.